News

AGROSPHERES ANNOUNCES NOVEL MODALITIES PARTNERSHIP WITH BAYER

AgroSpheres’ AgriCell technology will help deliver the next generation of high-performing, environmentally safe crop protection

CHARLOTTESVILLE, VA – AgroSpheres, INC., a leader in developing the next generation of environmentally friendly crop protection products, today announced a multi-year collaboration with Bayer to create novel modalities of biologicals for use as crop protection products.

“Teaming up with a leading global partner like Bayer helps us execute a mission we are both passionate about – transforming agriculture with better and more sustainable products for growers,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “This collaboration also brings us one step closer to establishing AgroSpheres as a next-generation biosciences company.”

AgroSpheres’ patented AgriCell manufacturing technology enables the production of encapsulated biomolecules with enhanced stability, field persistence and targeted delivery.

“AgroSpheres’ novel AgriCell systems are innovative technologies that will help us to explore new sustainable crop protection products,” said Rachel Rama, Head of Small Molecules for Bayer. “AgroSpheres’ cutting-edge scientific team will help us as we continue to improve innovative product offerings for our grower customers.”

Biomolecules such as peptides and nucleic acids have demonstrated great promise in the lab but have generally struggled to yield consistent results for commercial biological development. The AgriCell technology fills the missing link in delivering reliable field performance and opening new markets for high-performance biopesticides. Used with novel modalities, AgriCell technology will help deliver biopesticides that:

  • Outperform traditional biologicals
  • Are non-toxic to humans and animals
  • Are durable in the environment
  • Target specific pests
  • Help manage resistance

Read more here.

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights